• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    12/14/22 4:31:59 PM ET
    $CLVS
    $CSBR
    $HGEN
    $ICCC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CLVS alert in real time by email

    Gainers

    • PLx Pharma (NASDAQ:PLXP) stock increased by 10.6% to $0.23 during Wednesday's after-market session. The market value of their outstanding shares is at $6.5 million.
    • Clovis Oncology (NASDAQ:CLVS) shares rose 9.76% to $0.12. Trading volume for this security closed at 5.4 million, accounting for 125.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $16.7 million.
    • OpGen (NASDAQ:OPGN) stock increased by 9.09% to $0.18. Today's trading volume for this security ended up closing at 2.9 million shares, which is 72.0 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $9.6 million.
    • Champions Oncology (NASDAQ:CSBR) shares rose 8.26% to $4.98. The market value of their outstanding shares is at $67.3 million. The company's, Q2 earnings came out yesterday.
    • Humanigen (NASDAQ:HGEN) stock moved upwards by 8.18% to $0.14. At the close, Humanigen's trading volume reached 120.5K shares. This is 3.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $16.3 million.
    • Owlet (NYSE:OWLT) shares rose 6.78% to $0.71. The market value of their outstanding shares is at $81.5 million.

    Losers

    • Novavax (NASDAQ:NVAX) shares fell 13.3% to $14.94 during Wednesday's after-market session. This security traded at a volume of 598.6K shares come close, making up 11.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.1 billion.
    • Intelligent Bio Solutions (NASDAQ:INBS) shares decreased by 8.5% to $0.32. The market value of their outstanding shares is at $5.8 million.
    • Vallon Pharmaceuticals (NASDAQ:VLON) shares declined by 6.8% to $0.48. Vallon Pharmaceuticals's trading volume hit 21.2 million shares by close, accounting for 4115.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $6.1 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock declined by 5.85% to $0.43. The company's market cap stands at $5.5 million.
    • ImmuCell (NASDAQ:ICCC) stock fell 5.01% to $6.26. The company's market cap stands at $48.4 million.
    • Vincerx Pharma (NASDAQ:VINC) stock declined by 5.0% to $0.83. Trading volume for this security closed at 541.7K, accounting for 274.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $17.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CLVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLVS
    $CSBR
    $HGEN
    $ICCC

    CompanyDatePrice TargetRatingAnalyst
    Owlet Inc.
    $OWLT
    12/9/2025Outperform
    William Blair
    Novavax Inc.
    $NVAX
    10/24/2025$18.00Overweight
    Cantor Fitzgerald
    Novavax Inc.
    $NVAX
    8/28/2025$10.00Buy
    H.C. Wainwright
    Novavax Inc.
    $NVAX
    8/20/2025$7.00Neutral → Underperform
    BofA Securities
    Novavax Inc.
    $NVAX
    6/17/2025$6.00Sell
    Citigroup
    Owlet Inc.
    $OWLT
    4/23/2025$7.00Outperform
    Northland Capital
    Novavax Inc.
    $NVAX
    2/28/2025$19.00Buy
    BTIG Research
    Champions Oncology Inc.
    $CSBR
    9/12/2024$6.00Hold → Buy
    Craig Hallum
    More analyst ratings

    $CLVS
    $CSBR
    $HGEN
    $ICCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Turner Kathy V

    3 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    4/1/26 9:06:19 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Crawford Amanda

    4 - Owlet, Inc. (0001816708) (Issuer)

    3/27/26 9:50:09 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Brigham Michael F

    4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    3/24/26 7:57:33 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLVS
    $CSBR
    $HGEN
    $ICCC
    SEC Filings

    View All

    SEC Form NT 10-K filed by OpGen Inc.

    NT 10-K - CapForce Inc. (0001293818) (Filer)

    3/31/26 4:15:23 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form NT 10-K filed by TransCode Therapeutics Inc.

    NT 10-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/31/26 4:14:59 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by ImmuCell Corporation

    10-K - IMMUCELL CORP /DE/ (0000811641) (Filer)

    3/30/26 5:34:38 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLVS
    $CSBR
    $HGEN
    $ICCC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CLVS
    $CSBR
    $HGEN
    $ICCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: President and CEO Te Boekhorst Paul Francis Olivier bought $31,528 worth of Common Stock $0.10 par value per share (6,030 units at $5.23), increasing direct ownership by 163% to 9,738 units (SEC Form 4)

    4/A - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    12/4/25 4:11:39 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Te Boekhorst Paul Francis Olivier bought $48,588 worth of Common Stock $0.10 par value per share (9,785 units at $4.97) (SEC Form 4)

    4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    12/3/25 4:14:14 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Tomsche David Scott bought $15,554 worth of Common Stock $0.10 par value per share (3,266 units at $4.76), increasing direct ownership by 3% to 52,720 units (SEC Form 4)

    4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    11/28/25 8:12:55 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLVS
    $CSBR
    $HGEN
    $ICCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

    Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline  GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, President and Chief Executive Officer of Novavax.A specialist in internal medicine and pulmonary and critical care medi

    3/30/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

    PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. Upon joining the Board, Ms. Turner will serve as Chair of the Compensation and Stock Option Committee and as a member of the Audit Committee. Ms. Turner brings more than three decades of commercial executive leadership experience in global healthcar

    3/18/26 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Owlet Reports Fourth Quarter and Full Year 2025 Results; Initiates 2026 Guidance

    Owlet, Inc. ("Owlet" or the "Company") (NYSE:OWLT), the pioneer of smart infant monitoring, today reports financial results for the fourth quarter and full year ended December 31, 2025. Owlet's President and Chief Executive Officer, Jonathan Harris, and Chief Financial Officer, Amanda Twede Crawford, will host a conference call to review the Company's results and provide a business update today, March 5, 2026, at 4:30 p.m. ET. Q4 2025 Financial Highlights: Q4 Revenue of $26.6 million, up 29.6% from Q4 2024 Q4 Gross Profit of $12.6 million, up $1.7 million from Q4 2024 despite tariff cost impacts; Q4 Gross Margin of 47.6% Q4 Operating Loss of $4.9 million, compared to operating lo

    3/5/26 4:05:00 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    $CLVS
    $CSBR
    $HGEN
    $ICCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Owlet

    William Blair initiated coverage of Owlet with a rating of Outperform

    12/9/25 8:52:06 AM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    Cantor Fitzgerald resumed coverage on Novavax with a new price target

    Cantor Fitzgerald resumed coverage of Novavax with a rating of Overweight and set a new price target of $18.00

    10/24/25 8:05:21 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Novavax with a new price target

    H.C. Wainwright resumed coverage of Novavax with a rating of Buy and set a new price target of $10.00

    8/28/25 8:09:49 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLVS
    $CSBR
    $HGEN
    $ICCC
    Leadership Updates

    Live Leadership Updates

    View All

    Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

    Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline  GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, President and Chief Executive Officer of Novavax.A specialist in internal medicine and pulmonary and critical care medi

    3/30/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

    PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. Upon joining the Board, Ms. Turner will serve as Chair of the Compensation and Stock Option Committee and as a member of the Audit Committee. Ms. Turner brings more than three decades of commercial executive leadership experience in global healthcar

    3/18/26 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLVS
    $CSBR
    $HGEN
    $ICCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Vincerx Pharma Inc.

    SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 3:39:40 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

    SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 11:57:03 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Champions Oncology Inc.

    SC 13G/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

    11/14/24 9:53:10 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLVS
    $CSBR
    $HGEN
    $ICCC
    Financials

    Live finance-specific insights

    View All

    Owlet Reports Fourth Quarter and Full Year 2025 Results; Initiates 2026 Guidance

    Owlet, Inc. ("Owlet" or the "Company") (NYSE:OWLT), the pioneer of smart infant monitoring, today reports financial results for the fourth quarter and full year ended December 31, 2025. Owlet's President and Chief Executive Officer, Jonathan Harris, and Chief Financial Officer, Amanda Twede Crawford, will host a conference call to review the Company's results and provide a business update today, March 5, 2026, at 4:30 p.m. ET. Q4 2025 Financial Highlights: Q4 Revenue of $26.6 million, up 29.6% from Q4 2024 Q4 Gross Profit of $12.6 million, up $1.7 million from Q4 2024 despite tariff cost impacts; Q4 Gross Margin of 47.6% Q4 Operating Loss of $4.9 million, compared to operating lo

    3/5/26 4:05:00 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

    PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced its unaudited financial results for the year ended December 31, 2025. Management's Discussion: "Today we are reporting 2025 net operating income of $1.6 million, an increase of $3.3 million compared to 2024. These results were largely driven by a significant improvement in gross margin, reflecting higher volumes, manufacturing efficiencies, and price realization," commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. "Net loss

    3/4/26 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care